(Boursier.com) — eureKING , the French SPAC dedicated to health and more particularly to bioproduction in Europe, unveils its financial results for the period from April 1 to September 30, 2022. In line with expectations, eureKING did not record any revenues, no acquisition having was carried out during the period. The results therefore show a net loss of 3.26 ME due to the costs recorded.
eureKING aims to make a first acquisition of a European company specializing in biopharmaceutical subcontracting within 15 months of its first listing on Euronext Paris. In September 2022, eureKING obtained the TIBI label, an initiative of the French government and led by the General Directorate of the Treasury to bring together leading institutional investors who have committed to dedicate an initial amount of 6 billion euros, today today valued at more than 18 MdsE, for the financing of technology companies.
“These financial results are in line with expectations, the period having been marked by the success of our fundraising of 150 million euros and the listing of eureKING on Euronext in Paris. eureKING has solid financial resources and a international management team of experienced healthcare industry talent to accomplish its goal of becoming a major player in Europe in biomanufacturing,” said Michael Kloss, Managing Director of eureKING.
©2022-2023 Boursier.com